

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 1 of 26 of List of References

| | | |
|--|-----------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

| U.S. PATENT DOCUMENTS | | | | |
|------------------------------|-----------------|----------|------------------|---|
| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
| A01 | 4,343,782 | 8/10/982 | Shapiro | |
| A02 | 4,377,513 | 03/22/83 | Sugimoto et al. | |
| A03 | 4,658,019 | 04/14/87 | Kung et al. | |
| A04 | 4,703,008 | 10/27/87 | Lin | |
| A05 | 4,806,524 | 02/21/89 | Kawaguchi et al. | |
| A06 | 4,835,260 | 05/30/89 | Shoemaker | |
| A07 | 4,992,419 | 2/12/91 | Woog et al. | |
| A08 | 5,194,596 | 3/16/93 | Tischer et al | |
| A09 | 5,278,065 | 6/11/94 | D'Andrea | |
| A10 | 5,292,654 | 3/08/94 | Yoshimura | |
| A11 | 5,350,836 | 9/27/94 | Kopchick et al. | |
| A12 | 5,457,089 | 10/10/95 | Fibi et al. | |
| A13 | 5,547,933 | 08/20/96 | Lin | |
| A14 | 5,571,787 | 11/05/96 | O'Brien et al. | |
| A15 | 5,604,198 | 2/18/97 | Poduslo et al. | |
| A16 | 5,614,184 | 03/25/97 | Sytkowski et al. | |
| A17 | 5,618,698 | 04/08/97 | Lin | |
| A18 | 5,621,080 | 04/15/97 | Lin | |
| A19 | 5,625,035 | 04/29/97 | Clemons | |
| A20 | 5,661,125 | 08/26/97 | Strickland | |
| A21 | 5,696,080 | 12/09/97 | O'Brien | |
| A22 | 5,700,909 | 12/23/97 | O'Brien | |
| A23 | 5,714,459 | 02/03/98 | O'Brien | |
| A24 | 5,750,376 | 5/12/98 | Weiss et al. | |
| A25 | 5,756,349 | 05/26/98 | Lin | |
| A26 | 5,763,198 | 6/09/98 | Hirth et al | |
| A27 | 5,767,078 | 06/16/98 | Johnson et al. | |

| | |
|----------------------------------|------------------------|
| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|----------------------------------|------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 2 of 26 of List of References

| | | |
|---|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| FILING DATE | ART UNIT | |
| May 30, 2006 | 1647 | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|-----------------|----------|------------------|---|
| A28 | 5,773,569 | 06/30/98 | Wrighton et al. | |
| A29 | 5,824,672 | 10/20/98 | Simpkins et al. | |
| A30 | 5,830,851 | 11/03/98 | Wrighton et al. | |
| A31 | 5,835,382 | 11/10/98 | Wilson et al. | |
| A32 | 5,856,298 | 01/05/99 | Strickland | |
| A33 | 5,888,772 | 03/30/99 | Okasinski et al. | |
| A34 | 5,955,422 | 09/21/99 | Lin | |
| A35 | 5,997,865 | 12/7/99 | Bennett et al. | |
| A36 | 6,048,971 | 4/11/00 | Sytkowski et al. | |
| A37 | 6,071,970 | 6/06/00 | Mueller et al. | |
| A38 | 6,103,526 | 04/15/05 | Smith et al. | |
| A39 | 6,153,407 | 11/28/00 | Sytkowski et al. | |
| A40 | 6,165,783 | 12/26/00 | Weiss et al. | |
| A41 | 6,242,570 | 6/05/01 | Sytkowski | |
| A42 | 6,291,661 | 09/18/01 | Graddis et al. | |
| A43 | 6,340,742 | 1/22/02 | Burg et al. | |
| A44 | 6,399,336 | 6/4/02 | Paulson et al. | |
| A45 | 6,440,932 | 8/27/02 | Lehmann et al. | |
| A46 | 6,489,293 | 12/3/02 | Sytkowski et al. | |
| A47 | 6,521,245 | 2/18/03 | Zaharia | |
| A48 | 6,531,121 | 3/11/03 | Brines et al. | |
| A49 | 6,583,272 | 6/24/03 | Bailon | |
| A50 | 6,645,522 | 11/11/03 | Naeff et al. | |
| A51 | 7,214,532 | 5/08/07 | Stern et al. | |
| A52 | 7,309,687 | 12/18/07 | Brines et al. | |
| A53 | 7,345,019 | 3/18/08 | Brines et al. | |
| A54 | 2002/0031806 | 3/14/02 | Lee | |

| | |
|---------------------------|-----------------|
| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 3 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|-----------------|----------|-------------------|---|
| A55 | 2002/0052309 | 5/02/02 | Anagnostou et al. | |
| A56 | 2002/0061849 | 5/23/02 | Nielsen et al. | |
| A57 | 2002/0077294 | 6/20/02 | Kay et al. | |
| A58 | 2002/0081734 | 6/27/02 | Choi et al. | |
| A59 | 2002/0086816 | 7/04/02 | Brines et al. | |
| A60 | 2002/0142370 | 10/3/02 | Paulson et al. | |
| A61 | 2002/0160460 | 10/31/02 | Paulson et al. | |
| A62 | 2003/0003529 | 1/2/03 | Bayer | |
| A63 | 2003/0040037 | 2/27/03 | Bayer | |
| A64 | 2003/0072737 | 4/17/03 | Brines | |
| A65 | 2003/0077753 | 4/24/03 | Tischer | |
| A66 | 2003/0083251 | 5/01/03 | Westfenfelder | |
| A67 | 2003/0104988 | 6/5/03 | Brines | |
| A68 | 2003/0113871 | 6/19/03 | Lee et al. | |
| A69 | 2003/0118547 | 6/26/03 | Vandenberg | |
| A70 | 2003/0120045 | 6/26/03 | Bailon | |
| A71 | 2003/0124115 | 7/3/03 | Lee et al. | |
| A72 | 2003/0134798 | 7/17/03 | Brines et al. | |
| A73 | 2003/0166566 | 9/04/03 | Kinstler et al. | |
| A74 | 2004/0009902 | 1/15/04 | Boime | |
| A75 | 2004/0018978 | 1/29/04 | Campana et al. | |
| A76 | 2004/0091961 | 5/13/04 | Evans et al. | |
| A77 | 2004/0096447 | 5/20/04 | Yasuda et al. | |
| A78 | 2004/0122216 | 6/24/04 | Nielsen et al. | |
| A79 | 2004/0209812 | 10/21/04 | Farrell et al. | |
| A80 | 2004/0214236 | 10/28/04 | Brines et al. | |
| A81 | 2005/0176627 | 8/11/05 | Cerami et al. | |

| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH~~ /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 4 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|-----------------|----------|---------------|---|
| A82 | 2006/0034799 | 2/16/06 | Brines et al. | |
| A83 | 2006/0216757 | 9/28/06 | Brines et al. | |
| A84 | 2007/0298031 | 12/27/07 | Brines et al. | |
| A85 | 2008/0045412 | 02/21/08 | Brines et al. | |
| A86 | 09/200,938 | 4/13/00 | Brines et al. | |
| A87 | 09/547,220 | 4/11/00 | Brines et al. | |
| A88 | 09/718,829 | 11/21/00 | Brines et al. | |
| A89 | 09/716,963 | 11/21/00 | Brines et al. | |
| A90 | 09/716,960 | 11/21/00 | Brines et al. | |
| A91 | 10/554,517 | 10/25/05 | Brines et al. | |
| A92 | 11/283,024 | 11/18/05 | Cerami et al. | |
| A93 | 11/031,458 | 7/01/05 | Brines et al. | |
| A94 | 11/000,275 | 7/19/07 | Brines et al. | |

FOREIGN PATENT DOCUMENTS

| | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|-----|--|----------|---|---|---|
| B01 | CA 2,294,448 | 12/30/98 | Roche Diagnostics GmbH | | |
| B02 | DE 198 57 609 | 6/15/00 | Ehrenreich and Gleiter (w/English abstract) | | |
| B03 | EP 555880 | 8/18/93 | Bristol-Myers Squibb Company, Trustees of Dartmouth College, The General Hospital Corp. | | |
| B04 | EP 0640619 | 1/03/95 | Amgen Inc. | | |
| B05 | EP 0668 351 | 8/23/95 | Amgen, Inc. | | |
| B06 | EP 1064951 | 1/03/01 | F. Hoffmann-La Roche AG | | |
| B07 | JP-05092928 | 4/16/93 | Snow Brand Milk Prod Co., Ltd., (w/English abstract) | | |
| B08 | JP 5-246885 | 09/24/93 | JP-A Kokai (w/English Translation & Certificate of Translation) | | |

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 5 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

FOREIGN PATENT DOCUMENTS

| | | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|--|-----|---|----------|--|---|---|
| | B09 | WO 00/032772 | 6/8/00 | Eli Lilly & Co. | | |
| | B10 | WO 00/061164 | 10/19/00 | Kenneth S. Warren Laboratories | | |
| | B11 | WO 00/24893 | 5/4/00 | Amgen, Inc. | | |
| | B12 | WO 00/35475 | 06/22/00 | Ehrenreich, Hannelore (w/English abstract) | | |
| | B13 | WO 01/02017 | 1/11/01 | F. Hoffmann-La Roche AG | | |
| | B14 | WO 01/81405 | 1/11/01 | Amgen Inc. | | |
| | B15 | WO 01/82952 | 11/08/01 | Action Pharma APS | | |
| | B16 | WO 01/82953 | 11/08/01 | Action Pharma APS | | |
| | B17 | WO 01/87329 | 11/22/01 | F. Hoffmann-La Roche AG | | |
| | B18 | WO 02/053580 | 7/11/02 | Kenneth S. Warren Institute, Inc. | | |
| | B19 | WO 02/10743 | 2/07/02 | Ortho-McNeil Pharmaceutical, Inc. | | |
| | B20 | WO 02/14356 | 2/21/02 | Althoff, Claudia | | |
| | B21 | WO 02/49673 | 6/27/02 | F. Hoffmann-La Roche AG | | |
| | B22 | WO 03/029291 | 4/10/03 | F. Hoffmann-La Roche AG | | |
| | B23 | WO 04/003176 | 1/8/04 | The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S | | |
| | B24 | WO 04/004656 | 1/15/04 | The Kenneth S. Warren Institute, Inc. | | |
| | B25 | WO 04/022577 | 3/18/04 | Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc. | | |
| | B26 | WO 04/096148 | 11/11/04 | The Kenneth S. Warren Institute, Inc. | | |
| | B27 | WO 04/112693 | 12/29/04 | The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S | | |
| | B28 | WO 05/025606 | 3/24/05 | Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc. | | |
| | B29 | WO 05/032467 | 4/14/05 | Warren Pharmaceuticals, Inc. | | |
| | B30 | WO 05/084364 | 9/15/05 | The Kenneth S. Warren Institute, Inc. | | |
| | B31 | WO 05/117927 | 12/15/05 | The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S | | |
| | B32 | WO 06/002646 | 1/12/06 | Lundbeck A/S | | |
| | B33 | WO 06/014349 | 2/9/06 | The Kenneth S. Warren Institute, Inc., et al. | | |

| | |
|---------------------------|-----------------|
| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/~~

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 6 of 26 of List of References

| | | |
|--|-----------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

FOREIGN PATENT DOCUMENTS

| | | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|--|-----|---|----------|--|---|---|
| | B34 | WO 06/014466 | 2/9/06 | The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S | | |
| | B35 | WO 91/05867 | 5/02/91 | Amgen Inc. | | |
| | B36 | WO 92/08493 | 5/29/92 | Brigham & Women's Hospital | | |
| | B37 | WO 94/09257 | 4/28/94 | Kabushiki Kaisha Iseki Kaihatsu Koki (w/English abstract) | | |
| | B38 | WO 94/24160 | 10/27/94 | Brigham and Women's Hospital | | |
| | B39 | WO 95/05465 | 02/23/95 | Amgen, Inc. | | |
| | B40 | WO 96/14081 | 5/17/96 | Boehringer Mannheim GMBH | | |
| | B41 | WO 97/08307 | 3/6/97 | II Dong Pharmaceutical Co. Ltd. | | |
| | B42 | WO 97/18318 | 05/22/97 | Takara Shuzo Co., Ltd. (W/English abstract) | | |
| | B43 | WO 97/32895 | 9/12/97 | Regents of the University of California | | |
| | B44 | WO 98/10650 | 3/19/98 | East Carolina University | | |
| | B45 | WO 98/18926 | 05/07/98 | G.D. Searle & Co. | | |
| | B46 | WO 98/58660 | 12/30/98 | Boehringer Mannheim GMBH (w/English abstract) | | |
| | B47 | WO 95/31560 | 11/23/95 | Transkaryotic Therapies, Inc. | | |
| | B48 | WO 94/12650 | 6/9/94 | Transkaryotic Therapies, Inc. | | |
| | B49 | WO 93/09222 | 5/13/93 | Transkaryotic Therapies, Inc. | | |
| | B50 | WO 93/25221 | 12/23/93 | Alkerms Controlled Therapeutics | | |
| | B51 | WO 91/09955 | 7/11/91 | Applied Research Systems, ARS Holding MV | | |
| | B52 | WO 91/06667 | 5/16/91 | Cell Genesys, Inc. | | |
| | B53 | WO 90/11354 | 10/4/90 | Institut Pasteur (w/English abstract) | | |
| | B54 | WO 86/03520 | 6/19/86 | Genetics Institute, Inc. | | |
| | B55 | WO 85/02610 | 6/20/85 | Kirin-Amgen, Inc. | | |
| | B56 | WO 99/21966 | 5/06/99 | Neurospheres Holdings Ltd. | | |

| | |
|---------------------------|-----------------|
| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 7 of 26 of List of References

| | | |
|--|------------------|-------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT May 30, 2006 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C01 | Patent Interference No. 105,500 Ehrenreich v. Brines; Judgment Paper I, Declaration, Brines clean copy of claims, and Ehrenreich clean copy of claims (10/02/06) | |
| C02 | ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia," Shock, Vol. 22(1), pp 63-69 | |
| C03 | AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis," Brain Research, Vol. 952, pp. 128-134 | |
| C04 | AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins," Current Eye Research, Vol. 18:270-276 | |
| C05 | ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225. | |
| C06 | ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978 | |
| C07 | ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112. | |
| C08 | ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie der Demenz," Arzneiverordnung in der Praxis, Band 31, Sonderheft 4 (w/English abstract) | |
| C09 | ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291. | |
| C10 | AY et al., 1999, "Potential usefulness of basic fibroblast growth factor as a treatment for stroke," Cerebrovascular Disease, Vol. 9:131-135 | |
| C11 | BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits," Pediatric Res., Vol. 40(3):381-387 | |
| C12 | BARBER D.L., et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic activity," Blood, Vol. 98(11, part 2):132b-133b Abstract 4193 | |
| C13 | BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514 | |
| C14 | BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992 | |
| C15 | BARRON et al., 1994, "Alternatively spiced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," Gene, Vol. 147, pp. 263-8 | |
| C16 | BASKAYA et al., 1997, "The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats," Neuroscience Letters, Vol. 226:33-36 | |
| C17 | BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12. | |
| C18 | BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res. Commun. 164(2):788-795 | |
| C19 | BELAYEV et al., 1996, "Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats," Brain Research, Vol. 739:88-96 | |
| C20 | BENIT et al., 1993, "The 'WS motif' common to <i>v-mpl</i> and members of the cytokine receptor superfamily is dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8:787-790 | |

| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 8 of 26 of List of References

| | | |
|--|------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C21 | BENJAMIN et al., 1998, "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF," Development, Vol. 125, pp. 1591-1598 | |
| C22 | BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870 | |
| C23 | BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," PNAS Vol. 100(3):952-57 | |
| C24 | BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651 | |
| C25 | BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278 | |
| C26 | BESARAB et al., 1998, "The effects of normal as compared with low Hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoietin," New England Journal of Medicine, Vol. 339(9):584-590 | |
| C27 | BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy, PNAS, Vol. 101, pp. 823-828 | |
| C28 | BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc Natl Acad Sci U S A. Vol. 90:2618-22 | |
| C29 | BICKEL et al., 1994, " <i>In vivo</i> demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. Vol. 42(11):1493-7 | |
| C30 | BOISSEL et al., 1993 "Erythropoietin structure-function relationships," J. Biol. Chem. Vol. 268(21):15983-15993 | |
| C31 | BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci. Vol. 87(11):1308-15. | |
| C32 | BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," Bioorg. & Med. Chem., 9:557-562 | |
| C33 | BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," Cardiovascular Research, Vol. 63, pp. 208-16 | |
| C34 | BONDY, 1995, "Minireview -- The relaxation of oxidative stress and hyperexcitation to neurological disease," Society for Experimental Biology & Medicine, pp. 337-345 | |
| C35 | BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98:549-559 | |
| C36 | BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972 | |
| C37 | BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388. | |
| C38 | BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97(19):10526-10531 | |
| C39 | BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300 | |

| EXAMINER NY1-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 9 of 26 of List of References

| | | |
|---|-----------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C40 | BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," <i>Blood</i> , 81(6):1593-1597. | |
| C41 | BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," <i>Acta Derm Venereol.</i> , Vol. 82:411-417 | |
| C42 | BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," <i>The Journal of Histochemistry (Abstract)</i> www.jhc.org/cgi.contents/abstract/29/3/331 | |
| C43 | CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," <i>Annals New York Acad. Sci.</i> , 149:40-45. | |
| C44 | CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", <i>Int. J. Mol. Med.</i> 1:235-241 | |
| C45 | CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," <i>Proteins</i> 24:394-401 | |
| C46 | CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," <i>Cardiovasc Res.</i> 60(2): 315-325 | |
| C47 | CERNEUS et al., 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," <i>J Cell Biol.</i> Vol. 114(6):1149-58. | |
| C48 | CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," <i>Mol Brain Res.</i> , Vol. 81, pp. 29-42 | |
| C49 | CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," <i>Arch. Phys. Med. Rehabil.</i> , 65:370-374. | |
| C50 | COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," <i>Nature</i> , 191:1065-1067. | |
| C51 | COTES et al., 1966, "The International Reference Preparation of Erythropoietin," <i>Bull. Org. mond. Sante</i> , 35:751-760. | |
| C52 | COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, <i>Annals New York Acad. Sci.</i> , 149:12-17. | |
| C53 | CUNNINGHAM et al., 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," <i>Science</i> , Vol. 244:1081-1085 | |
| C54 | CUZZOCREA et al., 2005, "Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse," <i>Arthritis & Rheumatism</i> , Vol. 52(3):940-950 | |
| C55 | D'ANDREA et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," <i>Exp. Hematol.</i> 28(3):231-243 | |
| C56 | D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," <i>J. Clin. Invest.</i> 102(11):1951-1960 | |
| C57 | DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," <i>Nature</i> , Vol. 415, pp. 175-179 | |
| C58 | DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," <i>Biology of the Neonate</i> , 79(304):228-35 | |
| C59 | D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," <i>J. Clin. Invest.</i> 86(3):681-687 | |

| EXAMINER NY1-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with each communication to examiner.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. RMD

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 10 of 26 of List of References

| | | |
|--|------------------|----------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT May 30, 2006 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C60 | DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem. Vol. 10(1):32-7 | |
| C61 | DEL MASTRO et al., 1998, "Strategies for the use of epoetin alfa in breast cancer patients," The Oncologist, Vol. 3:314-318 | |
| C62 | DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," J. Immun Methods, Vol. 89:271-277 | |
| C63 | DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98 | |
| C64 | STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York, John Wiley & Sons, p. 122, p. 508 | |
| C65 | DIEM et al., 2005, "Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis," Brain, Vol. 128, pp. 375-385 | |
| C66 | DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," J. of Neuropathology and Experimental Neurology, Vol. 52(4):351-360 | |
| C67 | DIGICAYLIOLGU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720 | |
| C68 | DIPAOLI et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480 | |
| C69 | DISPERSYN et al. 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res. 43(4): 947-957 | |
| C70 | DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," J. of Cerebral Blood Flow Metabolism, Vol. 9, pp. 71-78 | |
| C71 | DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76 | |
| C72 | DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116(6):2293-2299. | |
| C73 | DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993 | |
| C74 | DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem.. 263(33):17516-17521. | |
| C75 | ECKART 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," Nephrol Dial Transplant, Vol. 17, Suppl 5, pp. 48-55 | |
| C76 | EGRIE et al., 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," Neph Dialysis Trans Vol 16 Suppl. 3, pp. 3-13 | |
| C77 | EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505 | |
| C78 | EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," Molecular Psychiatry, 9:42-54 | |
| C79 | EHRENREICH, 2004 "A boost for translational neuroscience," Science, Vol. 305:184-185 | |
| C80 | ELLIOTT et al.. 1997, "Mapping of the active site of recombinant human erythropoietin," Blood 89(2):493-502 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US

Express Mail No.: EV 654 895 286 US

Express Mail No.: EV 654 895 290 US

Express Mail No.: EV 654 895 309 US

Sheet 11 of 26 of List of References

| | | |
|---|------------------|-------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT May 30, 2006 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C81 | EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," <i>Transplantation Proceedings</i> , Vol. 36, pp. 2935-2938 | |
| C82 | ERBAYRAKTAR et al., 2003, "Asiaoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 100(11):6741-6 | |
| C83 | ERBAYRAKTAR et al., 2006, "Carbamylated erythropoietin reduces radiosurgically-induced brain injury," www.molmed.org , July 2006 | |
| C84 | EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5. | |
| C85 | EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782. | |
| C86 | FANTACCI et al. 2006, "Carbamylated erythropoietin ameliorates the metabolic stress induced <i>in vivo</i> by severe chronic hypoxia," <i>PNAS</i> , Vol. 103(46):17531-17536 | |
| C87 | FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", <i>Blood</i> 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001) | |
| C88 | FARUKI and KISS, 1995, "Erythropoietin, transfusion medical update, The institute for Transfusion Medicine, path.upmc.edu/consult/ria/july1995.html | |
| C89 | FDA Alert; 16 November 2006, updated 16 February 2007 and 9 March 2007, http://www.FDA.gov.CDER/DRUG/InfoSheets/HCP/RHE2007.HCP.htm | |
| C90 | FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," <i>Curr. Opin. Neurol.</i> 15(4):483-9 | |
| C91 | FISHBEIN et al. 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," <i>Am Heart Journal.</i> Vol. 101(5): 593-600 | |
| C92 | FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," <i>J. of Clinical Endocrinology and Metabolism</i> , Vol. 78(3):753-756 | |
| C93 | FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?" <i>Endocrinology</i> 143(1):2-10 | |
| C94 | FRESHNEY, R.I., 1983, "Culture of animal cells," A Manual of Basic Technique, pp. 3-4, A R. Liss, Inc. NY 1983 | |
| C95 | FRIDEN P. M., 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," <i>J. Controlled Release</i> , Vol. 46:117-28 | |
| C96 | FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," <i>American Journal of Kidney Disease</i> , Vol. 26(1), pp. 202-8 | |
| C97 | FUJITA et al.. 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," <i>Lukemia</i> , 11 Supl 3, pp. 444-5 | |
| C98 | FUKUDA et al., 1989. "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," <i>Blood</i> , 73(1):84-89. | |
| C99 | FUNG et al., 1990. "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," <i>Semin. Immunol.</i> 2:119-128 | |
| C100 | GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," <i>J. of Biological Chemistry</i> , Vol. 269(10):7224-7230 | |
| C101 | GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," <i>Stroke</i> , Vol. 27(4):761-765 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this page with the reference cited.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 12 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|------|--|---|
| | C102 | GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711 | |
| | C103 | GENBANK No. M59941, 1994 | |
| | C104 | GOLBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," J. Amer. Chem Soc., Vol. 124(4):544-555 | |
| | C105 | GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Action," Methods in Enzymology, Hormone Action Part B, Peptides Hormones, 1975 Academic Press, Vol. 28, pp. 109-121. | |
| | C106 | GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249(13):4202-4206. | |
| | C107 | GOLDWASSER et al., 1975, "An Assay for Erythropoietin <i>in Vitro</i> at the Milliunit Level," Endo., 97(2):315-323. | |
| | C108 | GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99(14):9450-9455 | |
| | C109 | GORIO et al., 2005, "Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury," PNAS, Vol. 102(45):16379-84 | |
| | C110 | GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99(8):5627-5631 | |
| | C111 | GREEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," Pharm. Ther. Vol. 80(2):123-147 | |
| | C112 | GREENBERG et al. 1995, Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy. J Sleep Res. 4(S1): 130-134 | |
| | C113 | GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x _L expression", Blood 94:87-96 | |
| | C114 | GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486 | |
| | C115 | GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," Nature Medicine, Vol. 8(7):718-724 | |
| | C116 | GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta. 1592:215-223 | |
| | C117 | GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects <i>in vivo</i> ," J. Biol. Chem. Vol. 277(31):27581-27584 | |
| | C118 | GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," Toxicological Sciences, Vol. 64:83-89 | |
| | C119 | HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Annals NY Academy of Sciences 149:516-527. | |
| | C120 | HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066 | |
| | C121 | HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and Bioengineering, Vol. 16:1069-1079 | |
| | C122 | HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with each reference cited.

ALL PREVIOUS REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 13 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| | in patients with lymphoproliferative malignances," Blood, Vol. 96(11), pp. 155b | |
| C123 | HARRIS et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209 | |
| C124 | HARRIS K.W. et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366 | |
| C125 | HARRIS K.W. et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319 | |
| C126 | HARRIS K.W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS | |
| C127 | HASSAN et al., 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594 | |
| C128 | HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267 | |
| C129 | HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59(1):153-156 | |
| C130 | HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743 | |
| C131 | HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754. | |
| C132 | HUWYLER and PARDRIDGE, 1998, Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem. 70(2):883-6 | |
| C133 | HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J Pharmacol Exp Ther. Vol. 282(3):1541-6. | |
| C134 | IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357 | |
| C135 | IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462. | |
| C136 | ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients," Nephron, Vol. 72, pp. 30-36 | |
| C137 | ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327 | |
| C138 | JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677 | |
| C139 | JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J of Neurological Sciences, Vol. 139:173-179 | |
| C140 | JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form without continuation to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BMD/

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 14 of 26 of List of References

| | | |
|---|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C141 | JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," <i>Hum. Gene Ther.</i> 7(13):1555-66 | |
| C142 | JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," <i>Chem Biol Interact.</i> Vol. 119-120:79-84 | |
| C143 | JOSSE et al., 1999, "Human serum paraoxanase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," <i>Chem Biol Interact.</i> Vol. 119-120:71-78 | |
| C144 | JUBINSKY et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression," <i>Mol. Med.</i> 2(6):766-773 | |
| C145 | JUBINSKY et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," <i>Blood</i> 90(5):1867-1873 | |
| C146 | JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", <i>Proc. Natl. Acad. Sci. USA</i> 99(16):10659-10664 | |
| C147 | JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", <i>Pediatr. Res.</i> 43(1):40-49 | |
| C148 | JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", <i>Early Human Devel.</i> 52(3):235-249 | |
| C149 | JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", <i>Soc. for Neuroscience Abstracts</i> 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001) | |
| C150 | JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," <i>Acta Paediatr. Supp.</i> Vol. 438, pp. 36-42 | |
| C151 | KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor," <i>Drug Metab Dispos.</i> Vol. 22(1):99-105 | |
| C152 | KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," <i>Glycobiology</i> , Vol. 11(12):1043-1049 | |
| C153 | KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. <i>Circulation</i> 108:1795-1797 | |
| C154 | KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," <i>Annals New York Acad. Sci.</i> , 149:18-24. | |
| C155 | KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration," <i>Ann. Neurol.</i> Vol. 56(6):815-826 | |
| C156 | KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," <i>Blood</i> 99(1):102-110 | |
| C157 | KISHIMOTO et al., 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver," <i>Am J Anat.</i> Vol. 178:241-9. | |
| C158 | KITAJIMA et al., 1994, "Effective combination therapy by recombinant erythropoietin and cepharanthin in a girl with refractory anemia," <i>Japanese J. Clin. Hematology</i> , Vol. 35(7):694-6988 (w/English abstract) | |
| C159 | KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," <i>Blood</i> . Vol 73(2):375-80 | |

EXAMINER
NYI-4088719v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 15 of 26 of List of References

| | | |
|---|------------------|----------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT May 30, 2006 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C160 | KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," <i>Obstetrics and Gynecology</i> , 96(5):826-828. | |
| C161 | KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons <i>in vitro</i> and <i>in vivo</i> ", <i>Brain Res.</i> 609:29-35 | |
| C162 | KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", <i>Behav. Neural Biol.</i> 62:237-243 | |
| C163 | GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," <i>J of Trauma</i> , Vol. 44(2):361-367 | |
| C164 | KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," <i>Behavioral Brain Research</i> , Vol. 153:77-86 | |
| C165 | KUROIWA et al., 1985, "The biphasic opening of the blood—barrier to proteins following temporary middle cerebral artery occlusion," <i>Acta Neurochirurgica</i> , Vol. 68:122-129 | |
| C166 | LAI et al., 1996, "The molecular role of the common gamma _c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." <i>Proc. Natl. Acad. Sci. USA</i> 93:231-235 | |
| C167 | LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", <i>J. Cardiovasc. Pharmacol.</i> 31(4):601-608 | |
| C168 | LEE P et al. 1998, Conditional lineage ablation to model human diseases. <i>Proc Natl Acad Sci U S A.</i> 95:11371-11376 | |
| C169 | LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," <i>Science</i> , Vol. 305, pp. 239-242 | |
| C170 | LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," <i>Br. J. Haematol.</i> 93:75-80 | |
| C171 | LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation <i>in vitro</i> ," <i>Exp. Hematol.</i> 32:36-44 | |
| C172 | LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", <i>Pediatr. Res.</i> 40(3):376-380 | |
| C173 | LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", <i>Neurosci.</i> 85(3):785-794 | |
| C174 | LIFE EXTENSION- WOUND HEALING; Wound: from the old english word wund, http://www.lef.org/protocols/prtcls-txt/t-prtcl-111.html 9/23/04, pp. 1-12, 2004 | |
| C175 | LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," <i>Anal. Biochem.</i> 219:207-217 | |
| C176 | LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", <i>Brain Res.</i> 692:143-153 | |
| C177 | LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." <i>Mol. Cell. Biol.</i> 14(10):6926-6935 | |
| C178 | LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", <i>Devel. Biol.</i> 166:159-169 | |
| C179 | LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", <i>Proc. Assoc. Am. Physicians</i> 108(6):449-454 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this sheet with communication to Office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 16 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C180 | LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272(51):32395-32400 | |
| C181 | LIU et al., 2007, "A potent erythropoietin-mimicking human antibody interacts through a novel binding site," Blood, Vol. 110(7):2408-2413 | |
| C182 | LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990 | |
| C183 | LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMIS, Vol. 101:777-783 | |
| C184 | LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103. | |
| C185 | LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017 | |
| C186 | MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood, Vol. 98(9):2872-2874 | |
| C187 | MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268 | |
| C188 | MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163 | |
| C189 | MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676 | |
| C190 | MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418 | |
| C191 | MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell., Vol. 49:437-8 | |
| C192 | MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268(15):11208-11216 | |
| C193 | MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269(30):19488-19493 | |
| C194 | MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70 | |
| C195 | MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202. | |
| C196 | MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," PNAS, USA 93:9471-9476 | |
| C197 | MCCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243 | |
| C198 | MEANS et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208 | |
| C199 | MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions – how big is the problem?", Ann. R. Coll. Surg. Engl., Vol. 72:60-3 | |
| C200 | MENZIES et al., 1990, "Extravastatin of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl. | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with each reference citation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 17 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| | | |
|-------------------|--|---|
| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
| | Vol. 51:220-222 | |
| C201 | MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465 | |
| C202 | MITSUMA, et al., 2006, "Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis," Biochemical and Biophysical Research Communications, Vol. 344:987-994 | |
| C203 | MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229 | |
| C204 | MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564. | |
| C205 | MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transsected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390 | |
| C206 | MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159. | |
| C207 | MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116 | |
| C208 | MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260 | |
| C209 | MUN et al., 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-7 | |
| C210 | MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353 | |
| C211 | MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co., . | |
| C212 | NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochemical and Biophysical Research Communications, Vol. 188(2):888-897 | |
| C213 | NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201 | |
| C214 | NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302 | |
| C215 | NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35 | |
| C216 | NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane," J. Biol. Chem. Vol. 260(12):7316-21 | |
| C217 | NIMTZ et al., 1993, "Characterization of a phosphorylated oligosaccharide from erythropoietin expressed in recombinant BHK cells," Glycoconj. J. Vol. 10, No. 4, page 259, S6.7 | |
| C218 | NISSENNON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416 | |
| C219 | NISSENNON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(1) suppl.:25-31 | |
| C220 | NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556 | |

| | |
|---------------------------|-----------------|
| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this document with the reference citation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 18 of 26 of List of References

| | | |
|--|---------------------------------|----------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C221 | OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(1):suppl. 2:12-15 | |
| C222 | OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11 | |
| C223 | OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332 | |
| C224 | ON-LINE MEDICAL DICTIONARY Lysozyme entry; website http://cancerweb.ncl.ac.uk/omd . Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne. Copyright 1997-2004. The CancerWEB Project. | |
| C225 | OPITZ CF et al. 1995, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats," Circulation. 92(2):253-261 | |
| C226 | OPITZ CF et al. 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J Am Coll Cardiol. 32(1): 261-267 | |
| C227 | PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69 | |
| C228 | PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteins to form a disulfide bond," Biochemistry, Vol. 26:2077-2082 | |
| C229 | PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. Vol. 259(1):66-60 | |
| C230 | Pardridge WM. 1998, "CNS drug design based on principles of blood-brain barrier transport." J Neurochem. Vol. 70:1781-92. | |
| C231 | PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17(7):713-731 | |
| C232 | PARK et al., 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704 | |
| C233 | PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635 | |
| C234 | PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16 | |
| C235 | PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773 | |
| C236 | PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980 | |
| C237 | PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropatholo Exp Neurol. Vol. 38(3):222-234 | |
| C238 | PFEFFER JM et al. 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260(5 Pt 2): H1406-1414 | |
| C239 | PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131 | |

| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this sheet with each submission to the Office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 19 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|------|---|---|
| | C240 | PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp.1765-1769 | |
| | C241 | PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTThP) of malignancy on bone resorption and formation in organ culture," Bone, Vol. 14:717-720 | |
| | C242 | PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 | |
| | C243 | PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709 | |
| | C244 | PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes, Vol. 32:1087-1091 | |
| | C245 | PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. Vol. 57:(1/2):347-35257:347-352 | |
| | C246 | QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 | |
| | C247 | REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, Vol. 9, pp. 1-8 | |
| | C248 | REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 | |
| | C249 | ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 | |
| | C250 | ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" The American Physiological Society, pp. R244-253 | |
| | C251 | ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19(6):1023-1030 | |
| | C252 | ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," Vis. Res., 37(24):3445-51 | |
| | C253 | RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 | |
| | C254 | RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Analytical Chemistry, 67(8):1442-1452 | |
| | C255 | SADAMOTO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32 | |
| | C256 | SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. Vol. 51, pp. 186-188 | |
| | C257 | SAKANAKA et al., 1998, " <i>In vivo</i> evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640 | |
| | C258 | SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in <i>in vitro</i> activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this sheet with all other information to be considered.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 20 of 26 of List of References

| | | |
|--|---------------------------------|----------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C259 | SAVINO et al., 2006, "Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis," J. of Neuroimmunology, Vol. 172, pp. 27-37 | |
| C260 | SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74(1):103-109 | |
| C261 | SCHIFFL and LANG, 1997, "Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium," Eur J. Med Res. Vol. 2:97-100 | |
| C262 | SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie (202)(2), pp 64-68 (Abstract Only) | |
| C263 | SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 | |
| C264 | SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464 | |
| C265 | SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256. | |
| C266 | SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48. | |
| C267 | SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist, Vol. 9, pp. 97-107 | |
| C268 | SILVA et al., 1999, "Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274(32):22165-22169 | |
| C269 | SIREN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98(7):4044-4049 | |
| C270 | SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. Vol. 88(1):18-29 | |
| C271 | SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99. | |
| C272 | STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181 | |
| C273 | STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 | |
| C274 | STEDMAN'S MEDICAL DICTIONARY, 27 th Ed. 2000, Lippincott, Williams, and Wilkins: Trauma and Inflammation, pp. 897-898, 1865-1866 | |
| C275 | STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4 | |
| C276 | STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484. | |
| C277 | STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Their Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89. | |
| C278 | STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717 | |

| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|---------------------------|-----------------|
|---------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this document with communication to Patent Office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 21 of 26 of List of References

| | | |
|--|------------------|-------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT May 30, 2006 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C279 | SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood—brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," <i>Acta Neuropathologica (Berl)</i> , Vol. 60:207-216 | |
| C280 | SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," <i>British J. Haematology</i> , 113:49-51. | |
| C281 | SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," <i>Can. J. Physiol. Pharmacol.</i> Vol. 73:1525-1535 | |
| C282 | SWISS ACCESSION No. P32927, October 1, 1993 | |
| C283 | SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," <i>Nature</i> 395:511-516 | |
| C284 | SZABO et al., 1998, "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 3867-3872 | |
| C285 | TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", <i>Int. J. Devl. Neurosci.</i> Vol. 13(3/4):241-252 | |
| C286 | TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," <i>J. Biochem.</i> , Vol. 81:395-402 | |
| C287 | TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. <i>J Am Coll Cardiol.</i> 25(1): 264-268 | |
| C288 | TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," <i>Nephrology Dialysis Transplantation</i> , Vol. 10:1733-1738 | |
| C289 | TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," <i>Biochem. Biophys. Res. Commun.</i> 148(1):443-448 | |
| C290 | URENA P. 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," <i>Press Medicale</i> , Vol. 31(11):505-514 (Abstract only) | |
| C291 | VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction," <i>JACC</i> , Vol. 46(11) pp. 125-133 | |
| C292 | VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," <i>Expert Opin. Biol. Ther.</i> Vol. 3(3):501-508 | |
| C293 | VEZZANI et al., 1999, "Interleukin-1-β Immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," <i>J. Neurosci.</i> , Vol 19(12):5054-65 | |
| C294 | VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," <i>J. Pharmacol Exp. Ther.</i> Vol 239(1):256-63 | |
| C295 | VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," <i>PNAS USA</i> , Vol. 93:9021-9026 | |
| C296 | WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," <i>Biol Reprod.</i> Vol. 38:1105-13. | |
| C297 | WEILAND et al., 1982, "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," <i>Blut</i> , 44:173-175. | |
| C298 | WELLS, 1990, "Additivity of mutational effects in proteins," <i>Biochemistry</i> , Vol. 29(37):8509-8517 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this page in patent application file.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 22 of 26 of List of References

| | | |
|---|-----------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C299 | WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846 | |
| C300 | WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820 | |
| C301 | WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. Vol. 23, pp. 61-70 | |
| C302 | WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244 | |
| C303 | WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344 | |
| C304 | WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p." Blood 76(1):24-30 | |
| C305 | WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:I-32-I-42 | |
| C306 | WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958 | |
| C307 | WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14(6):478-485 | |
| C308 | WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509 | |
| C309 | WU and PARDRIDGE, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. Oct; 279(1):77-83 | |
| C310 | WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259 | |
| C311 | XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. Vol. 101(5):1184-1194 | |
| C312 | YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500 | |
| C313 | YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915 | |
| C314 | YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665 | |
| C315 | YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18:129-38 | |
| C316 | YET et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719 | |
| C317 | YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826 | |
| C318 | YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063 | |
| C319 | YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction," | |

| EXAMINER NYI-4088719v2 | DATE CONSIDERED |
|--|-----------------|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with each reference cited. | |

ALL PREVIOUS REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
 Express Mail No.: EV 654 895 286 US
 Express Mail No.: EV 654 895 290 US
 Express Mail No.: EV 654 895 309 US

Sheet 23 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | Coleman et al. |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|---|
| | | Oncologist 1(5):337-339 | |
| C320 | ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-7 | | |
| C321 | ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. of Neuroscience Research, Vol. 83:1241-51 | | |
| C322 | ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7 | | |
| C323 | Office Action, Application No. 09/547,220, date mailed: May 8, 2002 | | |
| C324 | Office Action, Application No. 09/547,220, date mailed: June 13, 2002 | | |
| C325 | Office Action, Application No. 09/547,220, date mailed: October 22, 2002 | | |
| C326 | Office Action, Application No. 09/547,220, date mailed: January 28, 2003 | | |
| C327 | Office Action, Application No. 09/547,220, date mailed: December 2, 2003 | | |
| C328 | Office Action, Application No. 09/547,220, date mailed: September 22, 2004 | | |
| C329 | Office Action, Application No. 09/547,220, date mailed: June 6, 2005 | | |
| C330 | Office Action, Application No. 09/547,220, date mailed: February 22, 2006 | | |
| C331 | Office Action, Application No. 09/547,220, date mailed: August 31, 2006 | | |
| C332 | Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007 | | |
| C333 | Office Action, Application No. 09/718,829, date mailed: May 13, 2002 | | |
| C334 | Office Action, Application No. 09/718,829, date mailed: March 5, 2003 | | |
| C335 | Office Action, Application No. 09/718,829, date mailed: January 6, 2004 | | |
| C336 | Office Action, Application No. 09/718,829, date mailed: September 29, 2004 | | |
| C337 | Office Action, Application No. 09/718,829, date mailed: April 5, 2005 | | |
| C338 | Office Action, Application No. 09/718,829, date mailed: January 26, 2006 | | |
| C339 | Office Action, Application No. 09/718,829, date mailed: May 14, 2007 | | |
| C340 | Office Action, Application No. 09/718,829, date mailed: February 28, 2008 | | |
| C341 | Office Action, Application No. 09/716,963, date mailed: May 17, 2002 | | |
| C342 | Office Action, Application No. 09/716,963, date mailed: February 10, 2003 | | |
| C343 | Office Action, Application No. 09/716,963, date mailed: October 17, 2003 | | |
| C344 | Office Action, Application No. 09/716,963, date mailed: July 28, 2004 | | |
| C345 | Office Action, Application No. 09/716,963, date mailed: November 23, 2004 | | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 305 US

Sheet 24 of 26 of List of References

| | | |
|---|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|---|---|
| C346 | Office Action, Application No. 09/716,963, date mailed: March 18, 2005 | |
| C347 | Office Action, Application No. 09/716,963, date mailed: December 7, 2005 | |
| C348 | Office Action, Application No. 09/716,963, date mailed: July 21, 2006 | |
| C349 | Office Action, Application No. 09/716,963, date mailed: March 12, 2007 | |
| C350 | Office Action, Application No. 09/716,960, date mailed: August 26, 2002 | |
| C351 | Office Action, Application No. 09/716,960, date mailed: July 25, 2003 | |
| C352 | Office Action, Application No. 09/716,960, date mailed: March 8, 2004 | |
| C353 | Office Action, Application No. 09/716,960, date mailed: September 16, 2004 | |
| C354 | Office Action, Application No. 09/716,960, date mailed: January 19, 2005 | |
| C355 | Office Action, Application No. 09/716,960, date mailed: May 8, 2006 | |
| C356 | Office Action, Application No. 09/716,960, date mailed: February 1, 2007 | |
| C357 | Office Action, Application No. 09/716,960, date mailed: October 16, 2007 | |
| C358 | Office Action, Application No. 09/716,960, date mailed: December 6, 2007 | |
| C359 | Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008 | |
| C360 | Office Action, Application No. 09/717,057, date mailed: May 13, 2002 | |
| C361 | Office Action, Application No. 09/717,057, date mailed: November 1, 2002 | |
| C362 | Office Action, Application No. 09/717,057, date mailed: July 15, 2003 | |
| C363 | Office Action, Application No. 09/717,057, date mailed: April 5, 2004 | |
| C364 | Office Action, Application No. 09/717,057, date mailed: October 26, 2004 | |
| C365 | Office Action, Application No. 09/717,057, date mailed: April 5, 2005 | |
| C366 | Office Action, Application No. 09/717,057, date mailed: January 9, 2006 | |
| C367 | Office Action, Application No. 09/717,057, date mailed: October 10, 2006 | |
| C368 | Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007 | |
| C369 | Office Action, Application No. 09/717,053, date mailed: May 13, 2002 | |
| C370 | Office Action, Application No. 09/717,053, date mailed: July 16, 2002 | |
| C371 | Office Action, Application No. 09/717,053, date mailed: April 9, 2003 | |
| C372 | Office Action, Application No. 09/717,053, date mailed: October 15, 2003 | |
| C373 | Office Action, Application No. 09/717,053, date mailed: April 20, 2004 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this document with communication.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PMD/

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 25 of 26 of List of References

| | | |
|--|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT | |
| | Coleman et al. | |
| | FILING DATE | ART UNIT |
| | May 30, 2006 | 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C374 | Office Action, Application No. 09/717,053, date mailed: May 3, 2005 | |
| C375 | Office Action, Application No. 09/717,053, date mailed: January 20, 2006 | |
| C376 | Office Action, Application No. 09/717,053, date mailed: October 24, 2006 | |
| C377 | Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007 | |
| C378 | Office Action, Application No. 09/753,132, date mailed: January 25, 2002 | |
| C379 | Office Action, Application No. 10/185,841, date mailed: April 28, 2005 | |
| C380 | Office Action, Application No. 10/185,841, date mailed: January 18, 2006 | |
| C381 | Office Action, Application No. 10/185,841, date mailed: October 5, 2006 | |
| C382 | Office Action, Application No. 10/185,841, date mailed: June 27, 2007 | |
| C383 | Office Action, Application No. 10/188,905, date mailed: August 22, 2005 | |
| C384 | Office Action, Application No. 10/188,905, date mailed: March 21, 2006 | |
| C385 | Office Action, Application No. 10/188,905, date mailed: December 7, 2006 | |
| C386 | Office Action, Application No. 10/188,905, date mailed: January 8, 2008 | |
| C387 | Office Action, Application No. 10/351,640, date mailed: December 13, 2005 | |
| C388 | Office Action, Application No. 10/351,640, date mailed: August 28, 2006 | |
| C389 | Office Action, Application No. 10/351,640, date mailed: June 5, 2007 | |
| C390 | Office Action, Application No. 10/351,640, date mailed: March 19, 2008 | |
| C391 | Office Action, Application No. 10/612,665 date mailed: June 20, 2006 | |
| C392 | Office Action, Application No. 10/612,665 date mailed: February 23, 2007 | |
| C393 | Office Action, Application No. 10/612,665 date mailed: December 31, 2007 | |
| C394 | Office Action, Application No. 10/676,694, date mailed: May 31, 2007 | |
| C395 | Office Action, Application No. 10/520,140, date mailed: October 3, 2005 | |
| C396 | Office Action, Application No. 10/520,140, date mailed: June 19, 2006 | |
| C397 | Office Action, Application No. 10/520,140, date mailed: March 28, 2007 | |
| C398 | Office Action, Application No. 10/520,140, date mailed: December 27, 2007 | |
| C399 | LUNDBLAD 1991, "The Modification of cystine – cleavage of disulfide bonds," Chemical Reagents for Protein Modification, 2 nd Edition CRC Press, Boca Raton FL | |
| C400 | NEW COLLEGIATE DICTIONARY, 1975, G&C Merriam Company, pp. 973, 975 | |

| EXAMINER | DATE CONSIDERED |
|---------------|-----------------|
| NYI-4088719v2 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this sheet with each communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /BMD/

Express Mail No.: EV 654 895 272 US
Express Mail No.: EV 654 895 286 US
Express Mail No.: EV 654 895 290 US
Express Mail No.: EV 654 895 309 US

Sheet 26 of 26 of List of References

| | | |
|--|------------------------------------|-------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-042-999 | 10/573,905 |
| | APPLICANT Coleman et al. | |
| | FILING DATE May 30, 2006 | ART UNIT 1647 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | T |
|-------------------|--|---|
| C401 | BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912 | |
| C402 | Office Action, Application No. 10/185,841, date mailed: May 23, 2008 | |

| | | |
|---------------------------|-------------------------------|-----------------|
| EXAMINER NY1-4088719v2 | /Regina DeBerry/ (11/18/2008) | DATE CONSIDERED |
|---------------------------|-------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this sheet with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH... /BMD/